Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IgE therapy in IgE-ACPA-positive refractory rheumatoid arthritis
NL-OMON25810Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in rheumatoid arthritis (RA), sponsored by Leiden University Medical Center. Primary endpoints: Clinical disease activity by DAS44, Peripheral blood and synovial immunological parameters and 1 more. Planned start Jan 2010; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON25810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25810.